Seattle Genetics, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SGEN Nasdaq 8731 http://www.seattlegenetics.com/ 53.43 Stock Down -1.29

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Seattle Genetics, Inc.

Seattle Genetics (SGEN) Reports Positive Data for Adcetris - Jun 27th, 2017 8:48 am
Today's Research Reports on Trending Tickers: Exelixis and Seattle Genetics - Jun 27th, 2017 6:00 am
Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers - Jun 26th, 2017 7:32 pm
Why Frontier Communications, Seattle Genetics, and Arconic Slumped Today - Jun 26th, 2017 2:57 pm
Why Stratasys, Ltd. (SSYS), Arconic Inc (ARNC) and Seattle Genetics, Inc. (SGEN) Are 3 of Today’s Worst Stocks - Jun 26th, 2017 2:36 pm
Biotech Rally Stumbles As These Small Caps Pull Back - Jun 26th, 2017 2:10 pm
Seattle Genetics: A Disappointing Study…Or Was It? - Jun 26th, 2017 12:52 pm
Why Shares of Seattle Genetics, Inc. Got Whacked Today - Jun 26th, 2017 11:13 am
Seattle Genetics slumps as cancer drug data fails to impress - Jun 26th, 2017 10:36 am
J.P. Morgan Gives Thoughts on Seattle Genetics, Inc. (SGEN) Following Phase 3 Results - Jun 26th, 2017 9:18 am
UPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails to impress investors - Jun 26th, 2017 7:57 am
Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial - Jun 26th, 2017 6:07 am
Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma - Jun 26th, 2017 4:45 am
Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma - Jun 26th, 2017 4:45 am
Seattle Genetics Plunges After Issuing Stage 3 Trial Results - Jun 26th, 2017 3:34 am
Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug - Jun 21st, 2017 9:08 am
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt - Jun 21st, 2017 6:30 am
Adcetris-Opdivo Combination for Classical Hodgkin Lymphoma - Jun 21st, 2017 5:36 am
Updates on the Adcetris and Opdivo Combination - Jun 20th, 2017 1:36 pm
Seattle Genetics Halts Phase III Study on Leukemia Drug - Jun 20th, 2017 8:31 am